Narrative
In March 2016, a technology created from basic science research within my laboratory was spun out into a commercial vehicle called Skinbiotix ltd. In April 2017, Skinbiotix Ltd was floated on the AIM market of the London stock exchange and became SkinBioTherapeutics plc. The company now employs 4 people and is developing the technology into products.Impact date | 2012 |
---|---|
Category of impact | Economic, Health and wellbeing |
Impact level | Benefit |
Related content
-
Research output
-
Lactobacillus rhamnosus GG inhibits the toxic effects of Staphylococcus aureus on epidermal keratinocytes
Research output: Contribution to journal › Article › peer-review
-
Lactobacillus rhamnosus GG Lysate Increases Re-Epithelialization of Keratinocyte Scratch Assays by Promoting Migration
Research output: Contribution to journal › Article › peer-review
-
Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion
Research output: Contribution to journal › Article › peer-review
-
Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by lactobacillus and bifidobacterium lysates
Research output: Contribution to journal › Article › peer-review
-
The Effect of Formulation on Microbicide Potency and Mitigation of the Development of Bacterial Insusceptibility.
Research output: Contribution to journal › Article › peer-review
-
Press/Media
-
THE SUNDAY TIMES: The beauty of bio: does probiotic skincare work?
Press/Media: Expert comment
-
Activities
-
Exploring Human Host-Microbiome Interactions in Health and Disease 2017
Activity: Participating in or organising event(s) › Organising a conference, workshop, exhibition, performance, inquiry, course etc › Research
-
International scientific association for probiotics and prebiotics
Activity: Participating in or organising event(s) › Participating in a conference, workshop, exhibition, performance, inquiry, course etc › Research